Bad Miss For Biocon’s Bevacizumab In US But Firm In 'Good Place'

Indian Company Remains Upbeat As It Reports Full-Year Results

 
• By Anju Ghangurde
  
Pandemic induced misses dull momentum for Biocon • Source: Alamy

More from Earnings

More from Business